NDC80

Across TCGA pan-cancer cohorts, NDC80 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NDC80 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NDC80 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NDC80 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where NDC80 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.165	0.764	<.001	43	view →
LSCC	OS	Median	All	0.911	0.691	.007	20	view →
LUAD	OS	Median	All	0.695	0.941	.026	7	view →
OV	DFS	Median	All	0.855	1.000	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NDC80–PDAC (OS)

Open the PDAC breakdown →